A Comparison of Beta-blockers and Calcium Channel Blockers in Atrial Fibrillation

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 266 participants.

Also called NCT07904507

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 266 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07904507
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Switzerland (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07904507. Randomized; triple masking; primary purpose treatment. Start 2026-11 (anticipated); primary completion 2029-10 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Comparison of Beta-blockers and Calcium Channel Blockers in Atrial Fibrillation
Acronym
BRACE-AFib
Condition
Atrial Fibrillation (AF)
Intervention (Drug)
Diltiazem
Intervention (Drug)
Bisoprolol
Lead sponsor
University Hospital, Basel, Switzerland (class: other)
Collaborator
Swiss National Science Foundation (class: other)
Collaborator
Schweizerische Herzstiftung (class: other)
Collaborator
Freiwillige Akademische Gesellschaft Basel (class: not stated)
Collaborator
Clinical Trial Unit, University Hospital Basel, Switzerland (class: other)

Record details

Record id
cardio:ct-nct07904507
Content hash
3116cd98648801f76d2039a1dc02ed83bab3b0d1cd691e6ac821ea68dfebab3b